Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
Checked against the public recordLast updated Aug 3, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Jonsson Comprehensive Cancer Center
- Interventions being studied
- Procedure: radiofrequency ablation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of a primary or secondary intrathoracic malignancy * Any cell type or origin * Involving the intrapulmonary, mediastinal, or pleural/chest wall * Inoperable primary or metastatic cancer to the lung * Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy) * Single or multiple lesions that are non-contiguous with vital structures or organs such as: * Trachea * Heart * Aorta * Great vessels * Esophagus * Less than 5 cm in largest dimension * Accessible via percutaneous transthoracic route * Hepatic: * Coagulation profile normal
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Jonsson Comprehensive Cancer Center, UCLALos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 3, 2020. Always confirm current availability with the study team.